Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
about
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerAlternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancyRegulation and localization of transient receptor potential melastatin 2 in rat uterusPathways to tamoxifen resistance.The antiestrogens tamoxifen and fulvestrant abolish estrogenic impacts of 17α-ethinylestradiol on male calling behavior of Xenopus laevis.Identification of modulators of hair cell regeneration in the zebrafish lateral line.Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data.Emerging therapies for breast cancerTherapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop.Fulvestrant in advanced breast cancer: evidence to date and place in therapy.Glyoxalase I inhibition induces apoptosis in irradiated MCF-7 cells via a novel mechanism involving Hsp27, p53 and NF-κB.Potential of an in vitro toolbox combined with exposure data as a first step for the risk assessment of dietary chemical contaminants.The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cellsLow-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast CancerNaringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells.Expression and molecular consequences of inhibition of estrogen receptors in granulosa cells of bovine folliclesIn silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancerInduced protein degradation: an emerging drug discovery paradigm.Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage.Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sitesCombined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpressionICI 182,780 has agonistic effects and synergizes with estradiol-17 beta in fish liver, but not in testis.A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblastsEstradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy.17beta-Estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytesPKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenograftsAMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment
P2860
Q26777310-7B22D6AB-346B-4109-A905-4DEB7DD6E28BQ28572577-A166EBCE-CE70-4B75-90E3-86C54C532545Q28583932-6E291EE3-EEF7-4774-A1BF-A3DFE389FB39Q30441001-0D40ED10-CC1E-4BC7-8B7F-ACC7F24D7B65Q30463286-D08DFC14-1987-4A6D-A884-F54160F9F5CCQ30463838-2BC68A0F-F060-4D3E-9537-752BDF28C5DAQ30763243-1303C890-6050-4FFC-9C00-7DF3291F3F2AQ33617949-FB582597-D3D8-4D4D-9A59-42A36651775FQ33648503-8E4A64E4-AD0F-456B-A6E1-C9B354277B79Q33761468-4C19E22B-03F7-4840-AC52-61255A423AF0Q33887675-E17B6916-7F6D-46A8-95A2-3079D0172C76Q33918088-4F794C29-65BF-4402-A842-3E991507E6D3Q33962386-55970559-2586-4A6B-9C54-9267C00121F8Q34048154-72118CDD-950C-4A90-B46F-BEEB780C45C8Q34059561-9235AB74-613B-4D91-869D-172529C40FC5Q34078771-EFDE7734-7C05-4772-9254-0B103810AF03Q34410743-55C745F0-4958-48B9-9B06-156697BBC4DCQ34424735-5BF23DCA-4423-43A0-B923-5FD56B22BEAFQ34545841-17AC2AFD-8DC8-412C-8BC7-B30B15DEB94EQ34611621-AF8A4D63-3102-44A4-97B3-9041A7C9963CQ34626963-0023ED9F-DD30-4A46-A5BA-22DC1ACED8FCQ35029586-C85110EB-B3A6-4B69-BA9F-3D3328F363B6Q35142182-B6C48157-06BA-4956-8874-878C3E8A85F2Q35179559-5914E49B-1558-43C7-A2D7-4C46E9ECA912Q35201384-96923B24-36D3-40F8-90F6-0772FD5A9C70Q35585756-EB561773-83A8-4EC9-8356-8151DDD3265EQ35596991-C5605A6B-F88F-4326-84BD-651AD5CD158CQ35610581-2C742643-1090-4DD4-8829-D3E1B6CF17B0Q35748639-30744094-B7A7-4E01-BDF8-9E81AAFC1222Q35771300-F670D163-5EAA-4876-9410-82E3EC7303ACQ36024969-356A6B88-A655-4A0A-B114-9E7227CD98F8Q36037547-06A1F3C8-2D34-47A0-A213-3ADA880C4E93Q36248880-9D782A5F-AB55-4ADB-BF6D-8D78485597FEQ36437097-628E32EF-EF26-4A01-A298-9E863C8F1044Q36452355-0FF08587-05E1-4501-9A9D-B17FDB761CEFQ36534686-163657BA-D86E-49E2-9011-0CEC402AE319Q36578211-20B12CDB-FAAE-4450-9681-B3D7AC8E70DAQ36872440-31A16ABE-F5DE-4609-BC50-C9AF2D783DFDQ36916606-388DC9ED-AADB-4DD7-A6CE-636BA2672817Q36976172-85013267-6822-42A2-B094-C5FBAB3ABCE5
P2860
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@ast
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@en
type
label
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@ast
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@en
prefLabel
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@ast
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@en
P2093
P2860
P921
P356
P1476
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
@en
P2093
A Wakeling
C K Osborne
R I Nicholson
P2860
P2888
P356
10.1038/SJ.BJC.6601629
P407
P478
90 Suppl 1
P577
2004-03-01T00:00:00Z